Demand curve analysis of marijuana use among persons living with HIV.
Cannabis use disorder
Demand curve analysis
HIV
Marijuana
Opioid
Pain
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
05
09
2020
revised:
23
11
2020
accepted:
18
12
2020
pubmed:
17
1
2021
medline:
9
6
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
Despite medicalization and legalization of marijuana use, factors influencing demand for marijuana among persons living with HIV (PLWH) are incompletely understood. This knowledge gap undermines effective clinical management and policies. This study used demand curve simulation methods to address these issues. Marijuana-using PLWH (N = 119) completed experimental tasks to simulate amount of marijuana purchasing/use across different costs (money or time), and likelihood of reselling marijuana or marijuana therapeutic-use registration card in relation to profits. Additional simulations assessed purchasing of marijuana relative to other drug and non-drug goods. Simulated marijuana use decreased as money and time costs increased. Consumption was greater for participants with more severe Cannabis Use Disorder (CUD) and anxiety, intermediate pain levels, and past 90-day opioid use. Whereas few participants chose to sell their registration card, marijuana resale (diversion) steeply increased with profit. Likelihood of seeking marijuana therapeutic-use certification decreased in relation to registration card money cost, having to visit more physicians to get a signature, and delay to receiving the card, and increased with duration of certification. Participants who reported recent opioid use were more likely to seek certification. Consumption of several commodities assessed was independent of marijuana. Simulated marijuana use was related to participants' clinical profile (CUD, anxiety and pain symptoms, recent opioid use), and unrelated to purchasing other goods. Likelihood of seeking marijuana therapeutic-use registration was affected by several types of costs and recent opioid use. Participants were unlikely to divert registration cards. We discuss clinical and policy implications of these findings.
Sections du résumé
BACKGROUND
Despite medicalization and legalization of marijuana use, factors influencing demand for marijuana among persons living with HIV (PLWH) are incompletely understood. This knowledge gap undermines effective clinical management and policies. This study used demand curve simulation methods to address these issues.
METHODS
Marijuana-using PLWH (N = 119) completed experimental tasks to simulate amount of marijuana purchasing/use across different costs (money or time), and likelihood of reselling marijuana or marijuana therapeutic-use registration card in relation to profits. Additional simulations assessed purchasing of marijuana relative to other drug and non-drug goods.
RESULTS
Simulated marijuana use decreased as money and time costs increased. Consumption was greater for participants with more severe Cannabis Use Disorder (CUD) and anxiety, intermediate pain levels, and past 90-day opioid use. Whereas few participants chose to sell their registration card, marijuana resale (diversion) steeply increased with profit. Likelihood of seeking marijuana therapeutic-use certification decreased in relation to registration card money cost, having to visit more physicians to get a signature, and delay to receiving the card, and increased with duration of certification. Participants who reported recent opioid use were more likely to seek certification. Consumption of several commodities assessed was independent of marijuana.
CONCLUSIONS
Simulated marijuana use was related to participants' clinical profile (CUD, anxiety and pain symptoms, recent opioid use), and unrelated to purchasing other goods. Likelihood of seeking marijuana therapeutic-use registration was affected by several types of costs and recent opioid use. Participants were unlikely to divert registration cards. We discuss clinical and policy implications of these findings.
Identifiants
pubmed: 33453502
pii: S0376-8716(21)00019-3
doi: 10.1016/j.drugalcdep.2021.108524
pmc: PMC7889735
mid: NIHMS1663905
pii:
doi:
Substances chimiques
Hallucinogens
0
Medical Marijuana
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108524Subventions
Organisme : NIDA NIH HHS
ID : R01 DA032678
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Subst Use Misuse. 2009;44(11):1503-18
pubmed: 19938929
Addict Behav. 2001 Nov-Dec;26(6):803-25
pubmed: 11768546
Neuropsychopharmacology. 2009 Feb;34(3):672-80
pubmed: 18688212
Addiction. 1996 Sep;91(9):1261-4
pubmed: 8854356
Annu Rev Med. 2016;67:453-66
pubmed: 26515984
Addiction. 1998 Mar;93(3):321-35
pubmed: 10328041
J Pain Symptom Manage. 2005 Apr;29(4):358-67
pubmed: 15857739
Public Health Rev. 2014;35(2):1-18
pubmed: 25642015
AIDS Patient Care STDS. 1996 Feb;10(1):32-6
pubmed: 11361656
Exp Clin Psychopharmacol. 2015 Dec;23(6):504-12
pubmed: 26280591
AIDS. 2001 Mar 9;15(4):532-3
pubmed: 11242154
Harm Reduct J. 2005 Oct 04;2:18
pubmed: 16202145
J Psychoactive Drugs. 2000 Oct-Dec;32(4):435-43
pubmed: 11210205
J Acquir Immune Defic Syndr (1988). 1994 Oct;7(10):1057-63
pubmed: 8083823
AIDS Behav. 2017 Apr;21(4):1138-1148
pubmed: 27738780
Exp Clin Psychopharmacol. 2019 Apr;27(2):109-114
pubmed: 30475012
J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):43-6
pubmed: 15608523
Drug Alcohol Depend. 2013 Oct 1;132(3):654-9
pubmed: 23683791
Psychol Rev. 2008 Jan;115(1):186-98
pubmed: 18211190
AIDS Patient Care STDS. 2013 Sep;27(9):503-10
pubmed: 23991688
J Health Econ. 2020 Jan;69:102273
pubmed: 31865260
Drug Alcohol Depend. 2014 Aug 1;141:27-33
pubmed: 24878248
Addict Behav. 2007 Jan;32(1):49-62
pubmed: 16647822
J Gen Intern Med. 2019 Aug;34(8):1419-1426
pubmed: 30684198
Drug Alcohol Depend. 2017 Jan 01;170:174-180
pubmed: 27951424
J Psychopharmacol. 2020 Jun;34(6):654-662
pubmed: 32267192
Int Rev Psychiatry. 2018 Oct;30(5):91-106
pubmed: 30522342
Annu Rev Clin Psychol. 2014;10:641-77
pubmed: 24679180
Am J Public Health. 2018 Mar;108(3):e12
pubmed: 29412729
J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):38-45
pubmed: 14707790
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12624-12626
pubmed: 31182592
Am J Drug Alcohol Abuse. 2015 Mar;41(2):166-72
pubmed: 25375878
B E J Econom Anal Policy. 2010 Feb 17;10(1):
pubmed: 23536916
Prim Care. 2002 Jun;29(2):361-78
pubmed: 12391716
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):204-213
pubmed: 31579835
Psychopharmacology (Berl). 2019 Sep;236(9):2641-2652
pubmed: 30927021
J Int Assoc Physicians AIDS Care (Chic). 2009 Nov-Dec;8(6):342-6
pubmed: 19952287
Inj Epidemiol. 2019 Sep 2;6:38
pubmed: 31497489
Psychol Addict Behav. 2011 Jun;25(2):358-64
pubmed: 21443296
Addict Behav. 2007 Oct;32(10):2238-52
pubmed: 17478056
JAMA Intern Med. 2014 Oct;174(10):1668-73
pubmed: 25154332
Drug Alcohol Depend. 2016 Dec 01;169:26-32
pubmed: 27755989
Eur J Intern Med. 2018 Mar;49:20-22
pubmed: 29482739
AIDS Care. 2007 Apr;19(4):500-6
pubmed: 17453590
Drug Alcohol Depend. 2015 Jul 1;152:32-8
pubmed: 26002377
AIDS Care. 2008 Sep;20(8):1002-18
pubmed: 18608078
AIDS Patient Care STDS. 2016 Jul;30(7):324-38
pubmed: 27410496
Neurology. 2007 Feb 13;68(7):515-21
pubmed: 17296917
J Public Health Policy. 2002;23(4):413-39
pubmed: 12532682
AIDS Patient Care STDS. 2001 Mar;15(3):159-67
pubmed: 11313029
J Am Board Fam Med. 2014 Sep-Oct;27(5):583-93
pubmed: 25201928
Curr HIV/AIDS Rep. 2011 Dec;8(4):223-34
pubmed: 21858414
Am J Drug Alcohol Abuse. 2019;45(6):644-663
pubmed: 31603710
Addiction. 2019 Jan;114(1):112-118
pubmed: 30194789
Behav Processes. 2017 Jul;140:33-40
pubmed: 28347716
Exp Clin Psychopharmacol. 2014 Jun;22(3):211-21
pubmed: 24467370
Drug Alcohol Depend. 2014 Jun 1;139:33-40
pubmed: 24745475
J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):231-237
pubmed: 30865181
JAMA Intern Med. 2018 May 1;178(5):673-679
pubmed: 29610827
J Altern Complement Med. 2011 Sep;17(9):789-96
pubmed: 21875350
Addiction. 2018 Jun;113(6):987-988
pubmed: 29468760
Int J Drug Policy. 2019 Dec;74:152-159
pubmed: 31590091
Forum Health Econ Policy. 2019 Oct 16;22(2):
pubmed: 31618173
Addiction. 2020 May;115(5):817-831
pubmed: 31656048